Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 3 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 63 Leukemia, Myeloid, Acute 14 Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 11 Lymphoma, Non-Hodgkin 9 Lymphoma, Large B-Cell, Diffuse 9 Recurrence 8 Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Lymphoma 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Carcinoma, Small Cell 4 Ovarian Neoplasms 3 Leukemia 3 Hodgkin Disease 3 Extensive Stage Small Cell Lung Cancer 3 Small Cell Lung Cancer Extensive Stage 2 SCLC 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma, B-Cell 2 Lymphatic Diseases 2 Immunoproliferative Disorders 2 Hematologic Diseases 2 Glioblastoma 2 Ependymoma 2 Advanced Solid Tumors 2 Widespread Small Cell Lung Cancer 1 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Squamous Cell Carcinoma of Head and Neck 1

Interventions

Erlotinib Hydrochloride 2 exatecan 1 Filgrastim 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Familial ependymoma × Etoposide × Clear all

NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated

25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡